FindTrial
Sign In

Efficacy of Fuzheng Hejie Granules on COVID-19 infected children

Efficacy of Fuzheng Hejie Granules on COVID-19 infected children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005998
Enrollment
Unknown
Registered
2022-05-12
Start date
2022-04-28
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infected

Interventions

Control:None
Treatment:

Sponsors

Shanghai Children's Medical Center affiliated to school of medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) Asymptomatic COVID-19 infected children in Shanghai COVID-19 infection centralized isolation points, aged 1-18 years old. 2) Children didn't have serious diseases, nor the acute stage of chronic diseases, and did not need long-term oral or injection drugs; 3) Informed consent was obtained for this study.

Exclusion criteria

Exclusion criteria: 1) A history of serious adverse reactions of Fuzheng Hejie Granules. 2) Patients and guardians were unable to cooperate to complete the trial and follow-up.

Design outcomes

Primary

MeasureTime frame
CT value of COVID-19 nucleic acid detection;—

Countries

China

Contacts

Public ContactYin Yong
yinyong9999@163.com18930830705

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026